Advanced Bladder Cancer Clinical Trial

Trial Summary

A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies.

More Information on this Clinical Trial

Frequently Asked Questions

A Clinical Trial is a type of research study that examines how well a potential therapy works in humans.

The purpose of the Phase 1 portion of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors. The purpose of the Phase 2 portion is to estimate anti-tumor activity in subjects with advanced malignancies (relapsed or refractory pancreatic or advanced bladder cancer).

This clinical trial has certain criteria that a person has to meet to determine if they can participate. After you have discussed the trial with your doctor, specific tests will be done to see if you qualify for this study.

Rexahn Pharmaceuticals, Inc. is sponsoring this clinical trial.

There will be a total of 72 patients enrolled in this clinical trial.

Have your physician complete the contact form.